0000899243-22-038385.txt : 20221213
0000899243-22-038385.hdr.sgml : 20221213
20221213202450
ACCESSION NUMBER: 0000899243-22-038385
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221209
FILED AS OF DATE: 20221213
DATE AS OF CHANGE: 20221213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yale Catriona
CENTRAL INDEX KEY: 0001779308
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221460974
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS INC.
STREET 2: 170 HARBOR WAY 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-09
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001779308
Yale Catriona
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Development Officer
Common Stock
2022-12-09
4
A
0
19195
0.00
A
91268
D
Common Stock
2022-12-12
4
S
0
4598
43.18
D
86670
D
Common Stock
2022-12-12
4
S
0
402
43.77
D
86268
D
Stock Option (Right to Buy)
42.95
2022-12-09
4
A
0
86379
0.00
A
2032-12-08
Common Stock
86379
86379
D
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 30, 2021, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.68 to $43.67, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.69 to $43.91, inclusive.
This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
/s/ Jonathan Young, Attorney-in-Fact
2022-12-13